Quick Answer
Aspire Biopharma Holdings, Inc. reported Diluted EPS of $16.38 per share (loss) for fiscal year 2025.
Aspire Biopharma Holdings, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$16.38 | -762.1% |
| 2024 | -$1.90 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.04 | -300.0% | -300.0% |
| September 30, 2024 | -$0.01 | — | — |
- Aspire Biopharma Holdings, Inc. showed a decrease of -762.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2024–2025 period, Aspire Biopharma Holdings, Inc.’s diluted eps has declined by 762.1% (from $1.90 per share (loss) to $16.38 per share (loss)).
- The most recent figure is from Aspire Biopharma Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: